AbbVie (ABBV) Stock Buyback History
TTM buyback yield 0.24% · Shareholder yield (TTM) 0.24%.
AbbVie
ABBV
TTM buyback yield
0.24%
Shareholder yield (TTM)
0.24%
5Y share count change
7.0%
TTM buyback spend
$980.00M
SBC coverage (TTM)
1.03x
Diluted vs basic shares (annual)
Weighted average shares from the income statement: diluted (EPS denominator and typical buyback-yield basis) compared with basic.
Shares outstanding (annual)
Year-over-year change in diluted weighted average shares (industry-standard for EPS and per-share capital return). Green is fewer shares vs the prior fiscal year; red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield
Buybacks vs stock-based compensation
TTM coverage: 1.03x (buybacks ÷ SBC). Bars are fiscal-year totals.
Buyback spending history
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $980.00M | $955.00M | $25.00M | 1.79B | 1.0% | 0.24% |
| 2024 | $1.71B | $911.00M | $797.00M | 1.77B | 0.0% | 0.54% |
| 2023 | $1.97B | $747.00M | $1.23B | 1.77B | -0.3% | 0.72% |
| 2022 | $1.49B | $671.00M | $816.00M | 1.78B | 0.1% | 0.52% |
| 2021 | $934.00M | $692.00M | $242.00M | 1.78B | 6.2% | 0.39% |
| 2020 | $978.00M | $753.00M | $225.00M | 1.67B | 12.7% | 0.52% |
| 2019 | $629.00M | $430.00M | $199.00M | 1.48B | -4.0% | 0.48% |
| 2018 | $12.01B | $421.00M | $11.59B | 1.55B | -3.6% | 8.80% |
| 2017 | $1.41B | $365.00M | $1.04B | 1.60B | -1.7% | 0.92% |
| 2016 | $6.03B | $353.00M | $5.68B | 1.63B | -0.4% | 6.05% |
| 2015 | $7.59B | $282.00M | $7.30B | 1.64B | 1.7% | 7.95% |
| 2014 | $665.00M | $241.00M | $424.00M | 1.61B | 0.4% | 0.64% |
| 2013 | $320.00M | $212.00M | $108.00M | 1.60B | 1.7% | 0.38% |
| 2012 | $0.00 | $187.00M | −$187.00M | 1.58B | -3.0% | — |
| 2011 | $0.00 | $162.98M | −$162.98M | 1.63B | 0.0% | — |
| 2010 | $0.00 | $167.00M | −$167.00M | 1.63B | 0.0% | — |
| 2009 | $0.00 | $156.72M | −$156.72M | 1.63B | — | — |
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
TTM buybacks vs headroom (FCF − dividends, TTM)14% of headroom
Headroom $7.04B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Does AbbVie buy back its own stock?
- Yes, AbbVie (ABBV) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does AbbVie spend on share buybacks?
- Trailing twelve months (TTM) buyback spend is about $980.00M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is AbbVie's buyback yield?
- TTM buyback yield is about 0.24% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is AbbVie's shareholder yield?
- Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 0.24% combined (TTM-based where available).
Is AbbVie diluting shareholders?
- Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has AbbVie's share count changed?
- Diluted weighted average shares changed by about 7.0% over roughly five fiscal years (annual income statement data).